Zhang YF, et al. - In hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT), researchers assessed the impacts of postoperative adjuvant chemotherapy/transarterial chemoembolization (TACE) on survival/disease-free survival (DFS). The 1-, 3- and 5-year survival rates of HCC patients with PVTT can be improved by postoperative adjuvant chemotherapy vs surgery alone. Even so, only 1-year survival rate could be increased with postoperative TACE.